References
- Pan ZZ. mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 1998;19:94–8
- Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 1993;264:489–95
- Svingos AL, Colago EE, Pickel VM. Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. J Neurosci 1999;19:1804–13
- Werling LL, Frattali A, Portoghese PS, et al. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. J Pharmacol Exp Ther 1988;246:282–6
- Margolis EB, Hjelmstad GO, Bonci A, Fields HL. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 2003;23:9981–6
- Margolis EB, Lock H, Chefer VI, et al. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA 2006;103:2938–42
- Cichewicz DL, Haller VL, Welch SP. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther 2001;297:121–7
- Spanagel R, Almeida OF, Bartl C, Shippenberg TS. Endogenous κ-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology 1994;115:121–7
- Wang XM, Zhou Y, Spangler R, et al. Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Brain Res Mol Brain Res 1999;66:184–7
- Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010;210:121–35
- Yu G, Yan H, Gong ZH. Differential effects of acute and repeated morphine treatment on κ-opioid receptor mRNA levels in mesocorticolimbic system. Pharmacol Rep 2012;64:445–8
- Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic; 1998
- Mickiewicz AL, Napier TC. Repeated exposure to morphine alters surface expression of AMPA receptors in the rat medial prefrontal cortex. Eur J Neurosci 2011;33:259–65
- Narita M, Nagumo Y, Hashimoto S, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 2006;26:398–405
- Wang Y, Mitchell J, Moriyama K, et al. Age-dependent morphine tolerance development in the rat. Anesth Analg 2005;100:1733–9
- Russo SJ, Mazei-Robison MS, Ables JL, Nestler EJ. Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 2009;56:73–82
- Shippenberg TS, Zapata A, Chefer VI. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 2007;116:306–21
- Jordan BA, Cvejic S, Devi LA. Kappa opioid receptor endocytosis by dynorphin peptides. DNA Cell Biol 2000;19:19–27
- Margolis EB, Hjelmstad GO, Bonci A, Fields HL. Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons. J Neurophysiol 2005;93:3086–93
- Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 2012;69:857–96
- Zhu J, Luo LY, Mao GF, et al. Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1998;285:28–36
- Xia YF, He L, Whistler JL, Hjelmstad GO. Acute amphetamine exposure selectively desensitizes kappa-opioid receptors in the nucleus accumbens. Neuropsychopharmacology 2008;33:892–900